In conclusion, we report the generation of novel highly specific antibodies to CETN1, their evaluation in patients’ tumor microarrays, their utility in radioimmunoimaging, and effectiveness in RIT of experimental PDAC. The gene discussed is CETN1; the disease is neoplasm.